Vemlidy, illustration of tablet form (not a photo of the actual pack)

Illustrative image.

Vemlidy

Tenofovir

Prescription required

$1500.00

25mg · 3 × 30 tablets · 3 months supply

BrandBranded medicine· By Gilead SI

$500.00 per month

How long a supply?

1 month$500.00 a month
3 months$500.00 a month
6 months$500.00 a month
Supplied from Israel

Test mode: no payment is taken. View cart

Annual cost

$6000a year at this pack size

Prescription required

Upload your prescription after ordering, or send it to our pharmacy team. We dispense only against a valid prescription.

FDA boxed warningPosttreatment severe acute exacerbation of hepatitis b

Discontinuation of anti-hepatitis B therapy, including VEMLIDY, may result in severe acute exacerbations of hepatitis B. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who discontinue anti-hepatitis B therapy, including VEMLIDY. If appropriate, resumption of anti-hepatitis B therapy may be warranted.

Discontinuation of anti-hepatitis B therapy may result in severe acute exacerbations of hepatitis B. Hepatic function should be monitored closely in patients who discontinue VEMLIDY. If appropriate, resumption of anti-hepatitis B therapy may be warranted.

Read this with the rest of the clinical information

About Vemlidy

Overview

Vemlidy is an antiviral tablet containing tenofovir alafenamide, which the body converts to tenofovir. It treats chronic hepatitis B in adults and children aged 6 years and older who weigh at least 25 kg and have compensated liver disease, meaning the liver still functions adequately. It works by blocking a viral enzyme involved in hepatitis B virus replication.

What it treats

Chronic hepatitis B infection in adults and children aged 6 years and older who weigh at least 25 kg, with compensated liver disease.

Safety information

Side effects

Headache is the most common side effect, reported in at least 10% of patients. Serious side effects include severe worsening of hepatitis B, new or worsening kidney problems, lactic acidosis (a buildup of lactic acid in the blood), and severe liver enlargement with fat buildup. Contact your doctor if you develop symptoms or have test results suggesting any of these problems. Kidney function should be checked before or when starting treatment and monitored during treatment. If you also have HIV-1, Vemlidy alone is not recommended to treat it, as HIV-1 resistance may develop.

FDA boxed warning

Posttreatment severe acute exacerbation of hepatitis b

Discontinuation of anti-hepatitis B therapy, including VEMLIDY, may result in severe acute exacerbations of hepatitis B. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who discontinue anti-hepatitis B therapy, including VEMLIDY. If appropriate, resumption of anti-hepatitis B therapy may be warranted.

Discontinuation of anti-hepatitis B therapy may result in severe acute exacerbations of hepatitis B. Hepatic function should be monitored closely in patients who discontinue VEMLIDY. If appropriate, resumption of anti-hepatitis B therapy may be warranted.

A boxed warning is the strongest warning the US Food and Drug Administration requires on a medicine label. Text is taken from the official label, with internal section references removed.

Before taking this medicine

The FDA label lists no contraindications for Vemlidy. Caution is needed in people who have both hepatitis B and HIV-1. Vemlidy alone is not recommended to treat HIV-1, as HIV-1 resistance may develop. New or worsening kidney problems may occur. Kidney function, urine glucose and urine protein should be checked before or when treatment starts and monitored during treatment. People with chronic kidney disease also need blood phosphorus checks. Treatment should be stopped if symptoms or laboratory findings suggest lactic acidosis (a buildup of lactic acid in the blood) or significant liver toxicity, including severe liver enlargement with fat buildup.

Interactions

Vemlidy absorption may change when taken with medicines that strongly affect the transport proteins P-glycoprotein (P-gp) or BCRP. Ask your doctor or pharmacist to check for potential interactions before and during treatment.

Using Vemlidy

Dosing

Dosing is set by your prescriber. Each health care professional may prescribe medication differently according to a patient's medical history and condition, so follow the directions on your prescription label and speak to your doctor or pharmacist before changing anything.

Storage

Store below 25°C in a dry place, in the original pack, away from direct light and moisture. Do not keep it in a bathroom. Keep all medicines out of the sight and reach of children.

Clinical information on this page is summarised from the US FDA label VEMLIDY (TENOFOVIR ALAFENAMIDE) TABLET [GILEAD SCIENCES, INC.] (DailyMed, retrieved 19 September 2026).

Reviews

No reviews yet. Mail Order Drugs opened recently, and we publish reviews only from verified customers of this site, so this space stays empty until real ones arrive.

  • Every prescription order is checked by a licensed pharmacist before dispensing.
  • Payment pages are encrypted and card details never reach our servers.
  • We ship internationally, with cold-chain packing where a medicine needs it.

Related medicines